The results demonstrated that 1 patient had a deletion of E746 to A750 in exon 19, and 1 had L858R point in exon 21 mutations, but it has not been reported whether patients with EGFR mutations are effective in treatment.[13] A phase II TKI drug clinical study was conducted by Schilder et al detecting the mutations of exons 18 to 21 in 57 patients with ovarian cancer and primary peritoneal cancer.[14] Two cases of EGFR mutations were detected (2/57, 3.5%), all were deletions of exon 19 (delE746–A750). The gene discussed is EGFR; the disease is ovarian cancer.